Open AccessWhat Else Can We Use in The Discrimination of Activated MS Plaques in Addition to Diffusion MRI?
Author(s) -
Adem Karaman
Publication year - 2020
Publication title -
the eurasian journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.337
H-Index - 13
eISSN - 1308-8742
pISSN - 1308-8734
DOI - 10.5152/eurasianjmed.2020.19238
Subject(s) - medicine , tachypnea , bosentan , intensive care medicine , antagonist , disease , acute respiratory distress , endothelin receptor , receptor , lung , tachycardia
Acute respiratory distress syndrome is characterized by dyspnea at presentation, tachypnea on physical examination, findings of bilateral infiltration in chest radiography, refractory hypoxia, and high mortality. Although the main treatment approach is to address the underlying disease, there are also pharmacological and nonpharmacological options for supportive treatment. There is currently no pharmacological agent with proven efficacy in this syndrome, and many drugs are being studied for this purpose. One of these is the endothelin receptor antagonist bosentan.